INTERNATIONAL LIVER CANCER ASSOCIATION
International Liver Cancer Association 16th Annual Conference1-4 September 2022 , Madrid, Spain
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| P-01 | Deciphering the epigenetic dependencies of intrahepatic cholangiocarcinoma | Juan Lafuente-Barquero |  Received |
 |
|||
| P-03 | Metabolic characterization of non-alcoholic fatty liver disease-related hepatocellular carcinoma | Monika Lewinska | Received |
|
|||
| P-05 | Multidimensional analyses reveal immunosuppressive microenvironment of hepatitis B virus-related hepatocellular carcinoma | Yunhua Lee | Received |
|
|||
| P-06 | Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic-cholangiocarcinoma. | margherita rimini | Received |
|
|||
| P-08 | Identifying regulatory transcription factors in primary liver cancer cell lineage commitment using single cell ATAC sequencing | Amanda Craig | Received |
|
|||
| P-11 | A small hairpin of long noncoding RNA NIHCOLE promotes DNA double-strand break synapsis and ligation in hepatocellular carcinoma | Puri Fortes | Received |
|
|||
| P-12 | Association of RNA sequencingbased gene signatures and clinical outcomes of lenvatinib (len) pembrolizumab (pembro) in hepatocellular carcinoma (HCC): results from study 116/KEYNOTE-524 | Richard S. Finn | Received |
|
|||
| P-13 | Regulatory diversity of cancer stem cell marker expressions underscores intertumoral heterogeneity with therapeutic implication in hepatocellular carcinoma | Yu Man Tsui | Received |
|
|||
| P-14 | Distinct lymphoid cell populations in intrahepatic cholangiocarcinoma and hepatocellular carcinoma | Emily Kawaler | Received |
|
|||
| P-15 | Patient-derived organoids as new in vitro model for the study of hepatoblastoma | Laura Zanatto | Received |
|
|||
| P-16 | Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutated clusters | Margherita Rimini | Received |
|
|||
| P-19 | PLATELET C3G REGULATES HEPATOCARCINOMA PROGRESSION. | Cristina Baquero | Received |
|
|||
| P-20 | Utilizing MALDI imaging mass spectrometry to analyze N-glycosylation of patient-matched serum and tissue hepatocellular carcinoma | Andrew DelaCourt | Received |
|
|||
| P-21 | Dissecting the direct immunomodulatory potential of VEGF and PD-1 blockade in blood and tissue | Gloryanne Aidoo-Micah | Received |
|
|||
| P-22 | Kruppel-Like Factor 10 Deletion and Hepatocellular Carcinoma Development | Sung Hwan Yoo | Received |
|
|||
| P-23 | Evaluation of Stage Migration as a Predictor of Overall Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. A Multi-center Study | Neehar Parikh | Received |
|
|||
| P-24 | The tumor suppressor roles of miR-3185 in Hepatocellular Carcinoma | Inah Marie Aquino | Received |
|
|||
| P-25 | Dual role of TGF- signatures in human B viral multistep hepatocarcinogenesis: early and late responsive genes | Young Nyun Park | Received |
|
|||
| P-26 | IDH1 IN INTRAHEPATIC CHOLANGIOCARCINOMA: A COMPARATIVE GENOMIC ANALYSIS AND CLINICAL IMPACT. | margherita rimini | Received |
|
|||
| P-27 | Evaluating the roles of DNA-PK in hepatocellular carcinoma | Fanni Palinkas | Received |
|
|||
| P-28 | Preclinical proof-of-concept testing for potential synthetic lethality targeting homologous recombination-deficient hepatocellular carcinomas | Jihyun An | Received |
|
|||
| P-29 | The heterogeneity of Perivenous-type (CTNNB1-mutated) hepatocellular carcinomas involves inflammatory escape and STEM-cell features | Desquilles Lise | Received |
|
|||
| P-30 | Differential association of single nucleotide polymorphisms related to hepatocellular carcinoma in Hispanics and Caucasians | Andre Boonstra | Received |
|
|||
| P-31 | Analysis of distinct tumor associated macrophage (TAM) phenotypes and myeloid subsets in human intrahepatic cholangiocarcinoma (iCCA) compared to hepatocellular carcinoma (HCC) by single cell sequencing | Daniel Weissinger | Received |
|
|||
| P-32 | In vitro treatment of hepatocellular carcinoma organoids reveals additive rather than synergistic effects of doxorubicin and hypoxia | Lauriane Blukacz | Received |
|
|||
| P-33 | AURORA KINASE A IN HCC: A POSSIBLE ROLE IN PD-L1 REGULATION | Luca Grisetti | Received |
|
|||
| P-34 | HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis | Amit Singal | Received |
|
|||
| P-35 | Racial, Ethnic, and Socioeconomic Disparities in Treatment Delay among Patients with Hepatocellular Carcinoma in the United States | Amit Singal | Received |
|
|||
| P-36 | The importance of metabolic syndrome status for the risk of non-viral hepatocellular carcinoma: a nationwide study | Yuri Cho | Received |
|
|||
| P-37 | A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance | Ahlim Lee | Received |
|
|||
| P-38 | Healthcare costs and expenditures for Patients with Hepatocellular Carcinoma in the United States | Amit Singal | Received |
|
|||
| P-39 | Myosteatosis and visceral adiposity may be novel predictors for mortality in patients with hepatocellular carcinoma treated with sorafenib | Minkyu Kang | Received |
|
|||
| P-40 | Macrotrabecular-Massive histologic subtype is associated with ahigher riskof the recurrence of hepatoecelluar carcinoma | Sung Hwan Yoo | Received |
|
|||
| P-42 | Assessment of the compliance and influencing factors of liver cancer screening in a high-risk population: A cross-sectional study | Maomao Cao | Received |
|
|||
| P-44 | Predicting metabolic liver-specific fingerprint in Hepatocellular Carcinoma using a novel bioinformatics pipeline | Sergio Barace | Received |
|
|||
| P-45 | Viral Hepatitis Status is Not Associated with Increased Odds of Complications Compared to Non-Viral Hepatitis After Liver Resection for Hepatocellular Carcinoma: A National Surgical Quality Improvement Program Analysis | Luckshi Rajendran | Received |
|
|||
| P-47 | LI-RADS Category on MRI Predicts Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study | Sunyoung Lee | Received |
|
|||
| P-48 | Prevalence and pattern of alcohol consumption in patients with hepatocellular carcinoma. | María Varela Calvo | Received |
|
|||
| P-49 | Compliance of the screening for hepatocellular carcinoma in patients with chronic hepatitis B or C | Won Sohn | Received |
|
|||
| P-52 | Does HCC surveillance improve survival rate? A retrospective comparative study between patients diagnosed within and outside surveillance over a 10 year period A single centre study | Swetha Palanichamy | Received |
|
|||
| P-53 | Characteristics and survival of patients with hepatocellular carcinoma in natural history in a western country. | Maria Sánchez | Received |
|
|||
| P-54 | Epidemiology, real-world treatment patterns and clinical outcomes of systemic treatments in unresectable hepatocellular carcinoma: a systematic review | Cal Shephard | Received |
|
|||
| P-58 | A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B | Hye Won Lee | Received |
|
|||
| P-59 | Urinary Microbiome-Based Metagenomic Signature for Non-invasive Diagnosis of Hepatocellular Carcinoma | Eun Ju Cho | Received |
|
|||
| P-61 | Estimating postsurgical outcomes of patients with a single hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Risk scoring system development and validation | Bohyun Kim | Received |
|
|||
| P-63 | Protein biomarkers in HCC | Robin Zenlander | Received |
|
|||
| P-65 | Accurate diagnosis of HCC in cirrhotic patients with a novel protease assay compared to standard AFP | Tram Tran | Received |
|
|||
| P-67 | Noninvasive prediction of hepatocellular carcinoma development after oral antiviral therapy in patients with chronic hepatitis C: A multicenter study | Yu Rim Lee | Received |
|
|||
| P-68 | Differentiation hepatic angiomyolipoma and hepatocellular carcinoma in patients without risk of hepatocellular carcinoma | Hyungjin Rhee | Received |
|
|||
| P-69 | Early Detection of Hepatocellular Carcinoma via methylation-sensitive high-resolution melting-based Liquid Biopsy | Su Jong Yu | Received |
|
|||
| P-70 | Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy | Jae Seung Lee | Received |
|
|||
| P-72 | Hepatocellular carcinoma with fatty change: association of underlying liver disease and clinicopathologic characteristics | Jae Hyon Park | Received |
|
|||
| P-74 | FROM TISSUE TO SERUM- SPATIAL OMICS USED TO DEVELOP A NOVEL BIOMARKER FOR CHOLANGIOCARCINOMA | Shaaron Ochoa Rios | Received |
|
|||
| P-75 | Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma | Jeong Ah Hwang | Received |
|
|||
| P-77 | Low risk of seeding following percutaneous needle biopsy of intrahepatic cholangiocarcinoma (iCCA) | Gianluca Fornoni | Received |
|
|||
| P-78 | Optimal imaging criteria and modality to determine Milan criteria for prediction of post-transplant HCC recurrence after locoregional treatment | Mi-Suk Park | Received |
|
|||
| P-80 | Circulating cytokines reflective of the etiology-specific immune environment in cirrhosis and HCC | Andre Boonstra | Received |
|
|||
| P-81 | Albumin RNA in situ hybridization and filamin A are helpful for differentiation of small duct type intrahepatic cholangiocarcinoma from extrahepatic adenocarcinomas | Young Nyun Park | Received |
|
|||
| P-82 | Impact of the COVID-19 pandemic in the diagnosis and therapy of single hepatocellular carcinoma less than 3 cm in a western country. | Maria Valera | Received |
|
|||
| P-83 | Plasma cytokine levels and circulating DNA in plasma as biomarkers of response to immunotherapy in hepatocellular carcinoma | Elena Vargas-Accarino | Received |
|
|||
| P-86 | Diagnostic Performance of LI-RADS v2018 Versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using MRI: A Meta-Analysis of Comparative Studies | Sunyoung Lee | Received |
|
|||
| P-87 | Investigating historic aMAP scores in a population of NAFLD/NASH related Hepatocellular Carcinoma patients and studying variations in scores between cirrhotic and non-cirrhotic groups | Avisnata Das | Received |
|
|||
| P-89 | Screening with a reduction of liver cancer mortality: a systematic review and meta-analysis | Maomao Cao | Received |
|
|||
| P-93 | EURopean Field of Practice Study of Atezolizumab and Bevacizumab in HepatoCellular Carcinoma (EURAB-HCC) | Gloryanne Aidoo-Micah | Received |
|
|||
| P-94 | Treatment-related adverse events and improved survival in pts treated with atezolizumab plus bevacizumab: a global, real-world study. | Antonio DAlessio | Received |
|
|||
| P-97 | Previous variceal bleeding is associated with variceal bleeding under atezolizumab-Bevacizumab treatment | Manon Allaire | Received |
|
|||
| P-99 | Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Final analysis of the prospective, observational REFINE study | kirhan ozgurdal | Received |
|
|||
| P-100 | RAdiation SEgmentectomy for cuRative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): A prospective, single-centre, single-arm study | Alex Sher | Received |
|
|||
| P-101 | Trial in progress: Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria | Gonzalo Sapisochin | Received |
|
|||
| P-102 | Early Nivolumab addition to Regorafenib in patients with hepatocellular carcinoma progressing under first line therapy (GOING trial). Interim analysis and safety profile | Marco Sanduzzi Zamparelli | Received |
|
|||
| P-103 | A network meta-analysis of non-surgical locoregional therapies in patients with early hepatocellular carcinoma | Jihyun An | Received |
|
|||
| P-105 | Semaglutide prevents the progression of hepatocellular carcinoma in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH | Michael Feigh | Received |
|
|||
| P-106 | REACH-2 and REACH: Exploratory efficacy and safety results in Chinese hepatocellular carcinoma (HCC) patients with extrahepatic spread (EHS) | Junjun Liu | Received |
|
|||
| P-108 | Impact of dose adjustment on clinical outcome of lenvatinib-treated patients with advanced hepatocellular carcinoma (HCC) | Stephen Lam Chan | Received |
|
|||
| P-109 | Marked Interdisciplinary Differences in Treatment Strategies Exist in the Management of Combined Hepatocellular-cholangiocarcinoma Patients: An International Multicenter Evaluation of Hospital-wide Treatment Strategies | Marco Claasen | Received |
|
|||
| P-111 | A five year experience of assessing patients for liver transplantation in HCC: acceptance rates and outcomes. | Rosemary Faulkes | Received |
|
|||
| P-113 | R1 VASCULAR OR PARENCHYMAL MARGINS: WHAT IMPACT AFTER RESECTION OF INTRAHEPATIC CHOLANGIOCARCINOMA? | Mabilia Andrea | Received |
|
|||
| P-114 | Early variation of serum AFP predicts outcomes under atezolizumab/bevacizumab for advanced hepatocellular carcinoma | Claudia Campani | Received |
|
|||
| P-115 | Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: treatment and prognosis. | Marta Romero-Gutiérrez | Received |
|
|||
| P-116 | The cumulative incidence of hepatocellular carcinoma according to care cascade in patients with anti-HCV positive | HYUN WOONG LEE | Received |
|
|||
| P-117 | Renal disfunction in patients treated with atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma | Hitomi Takada | Received |
|
|||
| P-121 | PRIMER-1: A randomised phase II trial of Perioperative pembrolizumab and lenvatinib in resectable Hepatocellular Carcinoma (HCC) | Tim Meyer | Received |
|
|||
| P-122 | Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma - A Phase II Trial (NEOTOMA) | OKane Grainne | Received |
|
|||
| P-123 | Surveillance in Liver Cancer The SILVER study | Rohini Sharma | Received |
|
|||
| P-124 | Open label, randomised, phase 2 study to evaluate the safety and efficacy of sorafenib with or without MTL-CEBPA, an immune-modulatory saRNA upregulating C/EBP-a, as second line treatment in advanced hepatocellular carcinoma (OUTREACH 2) | Nagy Habib | Received |
|
|||
| P-125 | Multiple arterial-phase of gadoxetic acid-enhanced MRI improves diagnosis of hepatocellular Carcinoma: Multicenter propensity score-matched analysis | Sang Hyun Choi | Received |
|
|||
| P-126 | Clinical efficacy of stereotactic ablative body radiotherapy for oligometastatic hepatocellular carcinoma: a multi-institutional retrospective study (KROG 20-04) | Tae Hyung Kim | Received |
|
|||
| P-128 | CT Radiomic Features of Colorectal Cancer Liver Metastasis for Predicting Upcoming Disease Progression After Initial Systemic Chemotherapy | Joon-IL Choi | Received |
|
|||
| P-129 | TERT promoter mutations identified by ddPCR on FFPE samples: a surrogate marker of entry into liver carcinogenesis | Aurelie Beaufrere | Received |
|
|||
| P-135 | An assessment of ed microRNAs in patients with hepatitis B, hepatitis C and with hepatocellular carcinoma | Janusz Szemraj | Received |
|
|||
| P-136 | Interleukin-15 co-expression induces robust in vivo expansion and antitumor effect of Glypican-3-specific CAR T cells in a patient with liver cancer | Tannaz Armaghany | Received |
|
|||
| P-137 | Transcriptome profiling of the intermediate cell carcinoma of the primary liver cancer | Byungchan Jang | Received |
|
|||
| P-138 | Single-cell derived gene signatures identify responders to checkpoint inhibition in bulk transcriptome from advanced hepatocellular carcinoma | Sarah Cappuyns | Received |
|
|||
| P-139 | Fast Deep learning quantification of tumor infiltrating lymphocytes with minimal training dataset | Grousset Ruben | Received |
|
|||
| P-140 | MALDI imaging: a powerful tool to decipher intra-tumoral heterogeneity: combined hepato-cholangiocarcinomas as proof of concept | Elia Gigante | Received |
|
|||
| P-141 | An image-based machine learning pipeline for the prediction of liver resection complexity from preoperative CT scans | Omar Ali | Received |
|
|||
| P-142 | External Validation of the FSAC Model Using On-Therapy Response of Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B; a multicenter study | Jae Seung Lee | Received |
|
|||
International Liver Cancer Association 16th Annual Conference
1-4 September 2022 , Madrid, Spain
|
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 05/09/2022 TO 05/09/2023
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
